LEXX (lexariabioscience.com) Rega marang bathi mangsa ngarep
The patented DehydraTECH system significantly enhances the bioavailability of substances, which is reflected in the forward P/E dynamics of Lexaria Bioscience (LEXX). The value of 0.00 represents the latest reading of this metric. Share prices are supported by the success of nicotine delivery trials and royalties. The business is currently seeking a major strategic partner to license its developments without being acquired by another corporation.
Ringkesan rincian data analitis Lexaria (LEXX)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Lexaria Bioscience|LEXX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Lexaria Bioscience|LEXX - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Lexaria Bioscience Corp|LEXX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Lexaria Bioscience|Indikator likuiditas cepet lexariabioscience.com
- rincian asil keuangan lan kelipatan valuasi:
LEXX - Bathi perusahaan|Proyeksi bathi mangsa ngarep Lexaria Bioscience|LEXX - Pangali P/E|Rega marang bathi mangsa ngarep Lexaria Bioscience|LEXX - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Lexaria Bioscience Corp|LEXX - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Lexaria Bioscience|LEXX - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan lexariabioscience.com|LEXX - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lexaria Bioscience
Pambiji fundamental:LEXX Lexaria Bioscience Corp.
The investment appeal of Lexaria Bioscience (LEXX) is based on the monetization of DehydraTECH patents through licensing royalties, which ensures high margins in the absence of capital expenditures. The ratio of current market value to expected earnings, reflected via the company's forward P/E metric, allows for an assessment of the business valuation's fairness relative to future cash flows, confirming the fundamental stability of the intellectual property model.
Perusahaan pesaing
Prakiraan rega marang bathi HLN (Haleon)|KVUE (Kenvue Inc) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Verona Pharma Corp VRNA|Jyong Bio (MENS) - Rasio prakiraan rega marang bathi|LGND: Prakiraan rega marang bathi|amneal.com - Rasio kapitalisasi marang bathi mangsa ngarep|PRGO: Pangali Forward P/E|Alvotech S.A. - Pangali mangsa ngarep rega marang bathi|LQDA (Liquidia Technologies) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Galapagos Corp GLPG|Rega marang bathi mangsa ngarep ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Amphastar Pharmaceuticals, Inc. AMPH|Pacira Pharmaceuticals - Rega marang bathi mangsa ngarep|ARS Pharma - Pangali Forward P/E|Rasio prakiraan rega marang bathi Theravance Corp|AQST (Aquestive Therapeutics) - Prakiraan rega marang bathi|Rasio rega marang bathi mangsa ngarep SCPH|TECX (Tectonic Therapeutic Inc.) - Pangali Forward P/E|Pangali Forward P/E Tonix Pharma|Rega marang bathi mangsa ngarep China SXT Pharmaceuticals (SXTC)|EPRX (eupraxiapharma.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E BHST (BioHarvest Sciences)|Kapitalisasi marang proyeksi bathi invizyne.com (EXOZ)|Oramed Pharma - Pangali Forward P/E|ENTX - Pangali Forward P/E|HYFT (MindWalk) - Prakiraan rega marang bathi|ABVC BioPharma, Inc - Pangali mangsa ngarep rega marang bathi|CPIX (Cumberland Pharmaceuticals) - Pangali Forward P/E|Rega marang bathi mangsa ngarep QNTM|Pangali Forward P/E FGEN|Kapitalisasi marang proyeksi bathi Telomir Pharmaceuticals Inc|Rega marang bathi mangsa ngarep Rani Therapeutics Holdings, Inc. RANI|Synergy CHC Corp. (SNYR) - Rasio prakiraan rega marang bathi|RLYB - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi pulmatrix.com PULM|PTHL: Pangali Forward P/E|Prakiraan rega marang bathi Aptorum Group|LYRA (Lyra Therapeutics, Inc) - Pangali Forward P/E|Impact BioMedical, Inc. (IBO) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E TNFA|YCBD - Rasio prakiraan rega marang bathi|Rega marang bathi mangsa ngarep PainReform PRFX|CYTO: Rasio rega marang bathi mangsa ngarep|Lipella - Pangali Forward P/E|OptiNose Corp (OPTN) - Prakiraan rega marang bathi|PIRS: Pangali Forward P/E|Rasio prakiraan rega marang bathi procapsgroup.com (PROC)|Rega marang bathi mangsa ngarep Petros Pharmaceuticals, Inc.|Rega marang bathi mangsa ngarep QLI|Pangali Forward P/E SLRN|TFFP - Rasio prakiraan rega marang bathi
